Join
Live feed
·
PRReleasevia Quantisnow
Lexicon Pharmaceuticals Inc. logo

Lexicon's LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit

ByQuantisnow·Wall Street's wire, on your screen.
LXRX· Lexicon Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LXRX (Lexicon Pharmaceuticals Inc.) and more on Quantisnow.